Title: | Summary Measures for Clinical Trials with Survival Outcomes |
---|---|
Description: | Provides estimates of several summary measures for clinical trials including the average hazard ratio, the weighted average hazard ratio, the restricted superiority probability ratio, the restricted mean survival difference and the ratio of restricted mean times lost, based on the short-term and long-term hazard ratio model (Yang, 2005 <doi:10.1093/biomet/92.1.1>) which accommodates various non-proportional hazards scenarios. The inference procedures and the asymptotic results for the summary measures are discussed in Yang (2018, <doi:10.1002/sim.7676>). |
Authors: | Daewoo Pak and Song Yang |
Maintainer: | Daewoo Pak <[email protected]> |
License: | GPL (>= 3) |
Version: | 1.1.1 |
Built: | 2024-11-25 02:51:41 UTC |
Source: | https://github.com/cran/ClinicalTrialSummary |
ClinicalTrialSummary provides estimates of several summary measures of the treatment effect for design and analysis of clinical trials with survival outcomes, introduced in Yang (2018). These estimates are obtained under the short-term and long-term hazard ratio model (Yang and Prentice, 2005) which allows a range of time-varying hazard ratio shapes including crossing hazards situations.
Let be the hazard ratio function, where
and
are the hazard functions for the treatment group and the control group, respectively. The main function of the package,
ypsummary
, provides following five summary measures:
the average hazard ratio (AHR):
the weighted average hazard ratio (WAHR): where
the restricted superiority probability ratio (RSPR):
the restricted mean survival difference (RMSD):
the ratio of restricted mean times lost (RRMTL):
Note that all integrals are taken over for
less than or equal to the maximum follow-up duration of the trial. The asymptotic results for the average hazard ratio and the restricted mean survival difference were established in Yang and Prentice (2011) and Yang (2013), respectively. For other measures, the asymptotic results were established in Yang (2018).
The data used as an example in this package was from Gastrointestinal Tumor Study Group (1982) and the object returned by ypsummary
can be formatted to a table using the function summary
.
Package: | ClinicalTrialSummary |
Type: | Package |
Version: | 1.0.0 |
Date: | 2018-12-19 |
License: | GPL (>= 3) |
Daewoo Pak and Song Yang
Yang, S. (2018). Improving testing and description of treatment effect in clinical trials with survival outcomes. Statistics in medicine.
Yang S, and Ross L. Prentice (2005). Semiparametric analysis of short-term and long-term hazard ratios with two-sample survival data. Biometrika, 92.1:1-17.
Yang S, and Ross L. Prentice (2011). Estimation of the 2-sample hazard ratio function using a semiparametric model. Biostatistics, 12.2:354-368.
Yang S. (2013). Semiparametric inference on the absolute risk reduction and the restricted mean survival difference in clinical trials. Special issue on risk assessment. Lifetime Data analysis, 19:219-241.
Gastrointestinal Tumor Study Group (1982). A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Cancer.
library(ClinicalTrialSummary) data(ggas) result <- ypsummary(time=ggas$time, event=ggas$event, group=ggas$group, tau = 8.2) print(result) summary(result)
library(ClinicalTrialSummary) data(ggas) result <- ypsummary(time=ggas$time, event=ggas$event, group=ggas$group, tau = 8.2) print(result) summary(result)
Internal functions for the ClinicalTrialSummary package.
The Gastrointestinal Tumor Study Group (1982) compared chemotherapy with combined chemotherapy and radiation therapy, in the treatment of locally unresectable gastric cancer. Each treatment arm had 45 patients, with two observations of the chemotherapy group and six of the combination group censored. The plot of Kaplan-Meier survival curves show that the two curves cross at around 1000 days.
data(ggas)
data(ggas)
The data has the following information for the ninety subjects:
time
the vector for the pooled lifetimes of the two groups
event
the numeric vector of the right-censoring indicator (event = 1, censored = 0)
group
the numeric vector of the group indicator (treatment = 1, control = 0)
Gastrointestinal Tumor Study Group (1982). A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Cancer.
library(ClinicalTrialSummary) data(ggas)
library(ClinicalTrialSummary) data(ggas)
ypsummary
provides estimates of several summary measures of the treatment effect for design and analysis of clinical trials with survival outcomes, introduced in Yang (2018). The function utilizes the short-term and long-term hazard ratio model proposed in Yang and Prentice (2005), which can acccomodate various nonproportional hazard scenarios. The asymptotic properties of the summary measures are also discussed in Yang and Prentice (2011), Yang (2013), and Yang (2018).
## Default S3 method: ypsummary(time, event, group, tau, alpha = 0.05, tie = TRUE, bound = 50, repnum = 2000, ...)
## Default S3 method: ypsummary(time, event, group, tau, alpha = 0.05, tie = TRUE, bound = 50, repnum = 2000, ...)
... |
for S4 method only. |
time |
A numeric vector of observations pooled from the two groups |
event |
A numeric vector of the right-censoring indicator (event = 1, censored = 0) |
group |
A numeric vector of the group indicator (treatment = 1, control = 0) |
tau |
the upper end of the range used in defining the summary measures. Must be user-specified. |
alpha |
Significance level. The default value is 0.05. |
tie |
The default is |
bound |
A boundary ( |
repnum |
the number of replications for the resampling method in obtaining the limiting variance estimators of the measures. The default value is 2000. |
The function ypsummary
provides five summary measures of the treatment effect (see, Yang 2018), which can be utilized for various nonproportional haards scenarios:
the average hazard ratio (AHR):
the weighted average hazard ratio (WAHR): where
the restricted superiority probability ratio (RSPR):
the restricted mean survival difference (RMSD):
the ratio of restricted mean times lost (RRMTL):
where is the hazard ratio of the treatment group over the control group,
and
are the distribution functions for the treatment group and control group, respectively, and
and
. Note that all integrals are taken from 0 to
.
Estimate |
The point estimate for the corresponding summary meausure |
CI |
The confidence interval constructed by a re-sampling method. If the measure is a ratio, the z-value is the standardized log of the estimate. If the measure is a difference, the z-value is the standardized estimate. |
z-value |
Normally distributed value derived from the asymptotic results |
p-value |
the (two-sided) p-value using |
Yang, S. (2018). Improving testing and description of treatment effect in clinical trials with survival outcomes. Statistics in medicine.
Yang S, and Ross L. Prentice (2005). Semiparametric analysis of short-term and long-term hazard ratios with two-sample survival data. Biometrika, 92.1:1-17.
Yang S, and Ross L. Prentice (2011). Estimation of the 2-sample hazard ratio function using a semiparametric model. Biostatistics, 12.2:354-368.
Yang S. (2013). Semiparametric inference on the absolute risk reduction and the restricted mean survival difference in clinical trials. Special issue on risk assessment. Lifetime Data analysis, 19:219-241.
library(ClinicalTrialSummary) data(ggas) time <- ggas$time event <- ggas$event group <- ggas$group result <- ypsummary(time, event, group, tau=8.2) # tau must be supplied. result summary(result)
library(ClinicalTrialSummary) data(ggas) time <- ggas$time event <- ggas$event group <- ggas$group result <- ypsummary(time, event, group, tau=8.2) # tau must be supplied. result summary(result)